Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma

por T. P. MacGregor, R. Carter, R. S. Gillies, J. M. Findlay, C. Kartsonaki, F. Castro-Giner, N. Sahgal, L. M. Wang, R. Chetty, N. D. Maynard, J. B. Cazier, F. Buffa, P. J. McHugh, I. Tomlinson, M. R. Middleton, R. A. Sharma
Publicado 2018